At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 35 enrolled
Drug / intervention
Itacitinibdrug
Likely dose
Itacitinib 300 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Treatment of Non Severe Hemophagocytosis Lymphohistiocytosis With ITACITINIB a Phase II Prospective Trial
In Brief
A Phase 2 clinical trial evaluating Itacitinib for Adults Patients Having Non Severe HLH. Completed, enrolled 35 participants across 1 site.
Detailed Summary
This project aims to test the effectiveness of ITACITINIB in sporadic Hemophagocytosis Lymphohistiocytosis (HLHs)
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAdults Patients Having Non Severe HLH
CountriesFrance
CollaboratorsIncyte Corporation
Timeline
Phase 2CompletedFinished
20222023202420252026
First PostedSep 2021
Enrollment StartMay 2022
Primary CompletionApr 2025
Study CompletionOct 2025
TodayJul 2026
First PostedSep 30, 2021
Enrollment StartMay 3, 2022
Primary CompletionApr 3, 2025
Study CompletionOct 1, 2025
TodayJul 2, 2026
Enrollment to primary: 2.9 yearsPosted 4.8 years ago
Interventions
Itacitinibdrug
Administration of 300 mg of ITACITINIB per os every day for 30 days.